Description
BICNU VIAL 100MG + DILUENT 3ML
First action · last action
2017-02-14 · 2017-02-14
Transactions
1
First transaction's obligation
$89,846
Base + all options value (sum of deltas)
$89,846
Extent competed
NOT COMPETED UNDER SAP
Other than full & open authority
SAP NON-COMPETITION
Set-aside
NO SET ASIDE USED.
Offers received
1
SDVOSB flag on record
No
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING
Modification chain · 1 transaction
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2017-02-14+$89,846= $89,846
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2017-02-14 | +$89,846 | $89,846 | BICNU VIAL 100MG + DILUENT 3ML |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI JTAPCFM4NSL4)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C26024P0343 | 260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS | $10,312 | FY2024 |
| 36C24824P0748 | 248-NETWORK CONTRACT OFFICE 8 (36C248) · 6505 · DRUGS AND BIOLOGICALS | $56,559 | FY2024 |
| 36C25724P0104 | 257-NETWORK CONTRACT OFFICE 17 (36C257) · 6505 · DRUGS AND BIOLOGICALS | $41,571 | FY2024 |
| 36C24724P0133 | 247-NETWORK CONTRACT OFFICE 7 (36C247) · 6505 · DRUGS AND BIOLOGICALS | $10,393 | FY2024 |
| 36C24824P0161 | 248-NETWORK CONTRACT OFFICE 8 (36C248) · 6505 · DRUGS AND BIOLOGICALS | $27,010 | FY2024 |
| 36C24823P2639 | 248-NETWORK CONTRACT OFFICE 8 (36C248) · 6505 · DRUGS AND BIOLOGICALS | $31,862 | FY2023 |
Other recipients under 6505 from 626-NASHVILLE (00626) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36C24918F2128 | ABBVIE US LLC | 626-NASHVILLE (00626) | $8,874 | FY2018 |
| 36C24918N1818 | NEUROCRINE BIOSCIENCES, INC. | 626-NASHVILLE (00626) | $4,660 | FY2018 |
| 36C24918N1672 | ABBVIE US LLC | 626-NASHVILLE (00626) | $4,363 | FY2018 |
| 36C24918N1434 | GRIFOLS THERAPEUTICS LLC | 626-NASHVILLE (00626) | $12,807 | FY2018 |
| 36C24918N1404 | ABBVIE US LLC | 626-NASHVILLE (00626) | $8,874 | FY2018 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_VA24917P1555_3600_-NONE-_-NONE- · retrieved 2026-09-26.